GSK-2269557 is a potent and selective PI3Kδ inhibitor over the closely related isoforms.

GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively.

GDC-0941 2 MeSO3H salt is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM, with modest selectivity against p110β (11-fold) and p110γ (25-fold).

GDC-0326 is a potent and selective inhibitor of α-Isoform of Phosphoinositide 3-Kinase (PI3Kalpha inhibitor).

For the detailed information of GPI-1046, the solubility of GPI-1046 in water, the solubility of GPI-1046 in DMSO, the solubility of GPI-1046 in PBS buffer, the animal experiment (test) of GPI-1046, the cell expriment (test) of GPI-1046, the in vivo, in vitro and clinical trial test of GPI-1046, the EC50, IC50,and Affinity of GPI-1046, Please contact DC Chemicals..

Ch-319 (Ch319) is a triphenyltin (IV) carboxylate derivative that modulates AKT/FOXO3a signaling and inhibits progression of prostate cancer.

BAY 1082439 is a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN.

AT7867 Hcl is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase family.

AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3Kδ and PI3Kβ and 7.5-fold selectivity over PI3Kα.

AMPK activator 991 is an allosteric AMPK activator, activates non-phosphorylated Thr172 AMPK in vitro binds to α1β1γ1 and α2β1γ1 with Kd of 0.13 and 0.17 uM, respectively..

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity.

A potent, selective, orally bioavailable PI3Kδ inhibitor with IC50 of 2.6 nM.

A potent, allosteric, α1-selective small molecule activator of AMPK (EC50=20 nM).

A novel, potent, and selective p110δ PI3K inhibitor with IC50 of 0.1 nM in cell-based assays.

A novel specific p110β inhibitor with IC50 of 5.74 nM.

A novel potent, selective, orally available PI3Kδ inhibitor with IC50 of 31 nM.

A novel potent, pan-AMPK activator with similar potency for all AMPK heterotrimers.

A novel potent, orally active 3-phosphoinositide-dependent kinase-1 (PDK-1) with IC50 of 2 uM.

A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM.